Guggenheim Issues Pessimistic Forecast for Inventiva (NASDAQ:IVA) Stock Price

Inventiva (NASDAQ:IVA) had its target price reduced by Guggenheim from $12.00 to $9.00 in a research report sent to investors on Friday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

IVA has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Inventiva in a research report on Friday, March 28th. TD Cowen started coverage on shares of Inventiva in a research note on Friday, February 21st. They issued a “buy” rating and a $10.00 price objective on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Inventiva presently has an average rating of “Moderate Buy” and an average price target of $12.00.

Inventiva Stock Up 1.7 %

Shares of NASDAQ:IVA opened at $3.07 on Friday. The stock’s 50-day moving average is $2.77 and its 200-day moving average is $2.51. Inventiva has a 52-week low of $1.53 and a 52-week high of $3.98.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.